In the present study, we hypothesized that chronic oral treatment with the phthalideisoquinoline alkaloid noscapine, a B1R and B2R antagonist (Landen et al., 2004), ameliorates the CBF and CVR abnormalities in arcAβ mouse model of amyloidosis (Merlini et al., 2011). The gene discussed is BDKRB1; the disease is amyloidosis.